Delivery Order SPE2DB25D3109-SPE2DB26FP4NR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,387.94 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on October 23, 2025, with an ultimate completion date of October 24, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $15,601.71 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on September 12, 2025, with an ultimate completion date of September 15, 2025. This is a firm fixed-price, non-set-aside contract with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through open procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,063.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL units on August 26, 2025, with a completion date of August 27, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used pharmaceutical for treating autoimmune and inflammatory conditions, and this contract...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $16,470.37 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic pharmaceutical for treating autoimmune and...
- The Defense Logistics Agency awarded a delivery order valued at $10,610.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB26FP4NRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,132.20 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on October 24, 2025, with completion scheduled for October 27, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of supply under AmerisourceBergen's larger pharmaceutical support framework with the federal government. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, supporting customers including the Defense Health Agency and U.S. Coast Guard. HUMIRA (adalimumab) is a widely used biologic immunosuppressant medication, and this order fulfills ongoing pharmaceutical needs within the federal military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 10/24/25 |